Eli Lilly (LLY): FY24 Q3 earnings call, Oct 30, 2024
No Kalshi or Polymarket word markets were listed for Eli Lilly’s Oct 30, 2024 earnings call (FY24 Q3). The transcript is searchable below (quotes of at most 25 words).
UpdatedTranscript
quotes of at most 25 wordsSpeaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.
23 matches for “Impact”; 5 quoted, at least 25 words apart.
…progress related to our strategic deliverables. Revenue grew 42% after excluding the impact of revenue from the olanzapine portfolio, which we divested in Q3 2023.…
…our non-incretin medicines. As Dave mentioned, revenue grew 42% after excluding the impact of revenue from the olanzapine portfolio and was primarily driven by Mounjaro…
…operating expenses growth. The effective tax rate was 37.6%, reflecting the unfavorable impact of non-deductible acquired IPR&D charges. Other than the impact of acquired IPR&D,…
…these products. Europe revenue grew 39% in constant currency when excluding the impact of the divestiture of the olanzapine portfolio. This growth was primarily driven…
…This increase was driven by volume growth of Tyvyt and favorable pricing impacts for Humalog. Finally, Japan grew 17% in revenue in constant currency. Volume…
Agents: this page as TSV at /api/v1/appearances/eli-lilly:2024-10-30:earnings_call · words: /api/v1/brief?appearance=eli-lilly:2024-10-30:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP